



NYRx Notice to Providers: Baclofen Solution

September 18, 2026

Baclofen solution has been added to the [NYRx Cost Optimization Program](#). Drugs added to the NYRx Cost Optimization Program have entered the market with **substantially higher** launch prices than equally efficacious, cost-effective alternatives. They lack additional clinical utility, while others lack clear medical necessity for those specific formulations and dosages. Baclofen solution will require a Manual Review by NYRx for consideration of coverage approval.

There are clinically- and cost-effective options of the same drug available on the [NYRx Preferred Drug List \(PDL\)](#), such as baclofen tablets. **Preferred drugs will not require prior authorization if the required coverage parameters are found in the member's Medicaid claim history at the time of pharmacy claim submission.**

Preferred Drugs	Non-Preferred Drugs	Coverage Parameters
XI. Musculoskeletal Agents		
Skeletal Muscle Relaxants		
baclofen tablet chlorzoxazone 500 mg F/Q/D cyclobenzaprine 5 mg, 10 mg tablet F/Q/D dantrolene methocarbamol F/Q/D orphenadrine ER F/Q/D tizanidine tablet F/Q/D	Amrix® F/Q/D Atmeksi® F/Q/D, MR baclofen 15 mg tablet baclofen solution MR baclofen suspension (gen Flegsuvy™) carisoprodol ST, F/Q/D chlorzoxazone F/Q/D chlorzoxazone 250 mg F/Q/D, MR cyclobenzaprine 7.5 mg F/Q/D cyclobenzaprine ER capsule (gen Amrix) F/Q/D Dantrium® Flegsuvy™ Lyvispah™ metaxalone F/Q/D metaxalone 640 mg tablet F/Q/D, MR methocarbamol 1000 mg F/Q/D, MR Ontralfy™ F/Q/D, MR orphenadrine-aspirin-cafeine F/Q/D, MR Ozobax® MR Ozobax® DS MR Soma® ST, F/Q/D tizanidine capsule F/Q/D tizanidine 8 mg capsule F/Q/D, MR Tonmya™ F/Q/D, MR Zanaflex® F/Q/D	STEP THERAPY (ST) - Trial with 1 analgesic and 2 skeletal muscle relaxants prior to use of carisoprodol FREQUENCY/QUANTITY/DURATION (F/Q/D) - PA is required for a quantity exceeding a 14-day supply and up to one (1) refill for initial fill of an antispasmodic skeletal muscle relaxant Carisoprodol – Maximum 4 units per day, 28-day supply

Resources

- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)
- [NYRx Preferred Drug Quick List](#)

- [NYRx Prior Authorization Submission Guide](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Visit the [NYRx Education & Outreach website](#) for more information.